JP2007502864A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007502864A5 JP2007502864A5 JP2006533279A JP2006533279A JP2007502864A5 JP 2007502864 A5 JP2007502864 A5 JP 2007502864A5 JP 2006533279 A JP2006533279 A JP 2006533279A JP 2006533279 A JP2006533279 A JP 2006533279A JP 2007502864 A5 JP2007502864 A5 JP 2007502864A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- subject
- alkyl
- alkenyl
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US44617003A | 2003-05-23 | 2003-05-23 | |
| US10/457,034 US7354932B2 (en) | 2001-12-21 | 2003-06-06 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy |
| PCT/US2004/015977 WO2004106493A2 (en) | 2003-05-23 | 2004-05-21 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007502864A JP2007502864A (ja) | 2007-02-15 |
| JP2007502864A5 true JP2007502864A5 (https=) | 2007-07-19 |
Family
ID=33493026
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006533279A Pending JP2007502864A (ja) | 2003-05-23 | 2004-05-21 | 有効性を高めたケモカインレセプタ結合複素環化合物 |
Country Status (5)
| Country | Link |
|---|---|
| US (6) | US7354932B2 (https=) |
| EP (1) | EP1628533A4 (https=) |
| JP (1) | JP2007502864A (https=) |
| CA (1) | CA2522535C (https=) |
| WO (1) | WO2004106493A2 (https=) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220409589A1 (en) * | 2001-12-21 | 2022-12-29 | Genzyme Corporation | Chemokine receptor binding heterocyclic compounds with enhanced efficacy |
| US7354932B2 (en) * | 2001-12-21 | 2008-04-08 | Anormed, Inc. | Chemokine receptor binding heterocyclic compounds with enhanced efficacy |
| WO2004092169A1 (ja) * | 2003-04-18 | 2004-10-28 | Ono Pharmaceutical Co., Ltd. | スピロピペリジン化合物およびその医薬用途 |
| EP1730113B1 (en) * | 2004-03-15 | 2016-12-28 | Genzyme Corporation | Process for the synthesis of a cxcr4 antagonist |
| DE102004023506A1 (de) | 2004-05-10 | 2005-12-01 | Grünenthal GmbH | Kettenverlängerte substituierte Cyclohexyl-1,4-diamin-Derivate |
| EP1790639B1 (en) * | 2004-08-27 | 2014-03-26 | Ono Pharmaceutical Co., Ltd. | Spirocyclic compounds and their use as cxcr4-antagonists |
| TW200619206A (en) * | 2004-09-29 | 2006-06-16 | Anormed Inc | Chemokine-binding heterocyclic compound salts, and methods of use thereof |
| UA87884C2 (uk) * | 2004-12-03 | 2009-08-25 | Мерк Энд Ко., Инк. | Безводна кристалічна калієва сіль інгібітора віл-інтегрази |
| AU2006203826A1 (en) | 2005-01-07 | 2006-07-13 | Emory University | CXCR4 antagonists for the treatment of HIV infection |
| WO2006096444A2 (en) * | 2005-03-04 | 2006-09-14 | Smithkline Beecham Corporation | Chemical compounds |
| EP1904501A2 (en) * | 2005-07-11 | 2008-04-02 | Smithkline Beecham Corporation | Chemical compounds |
| WO2007058322A1 (ja) | 2005-11-18 | 2007-05-24 | Ono Pharmaceutical Co., Ltd. | 塩基性基を含有する化合物およびその用途 |
| JP2009531283A (ja) | 2006-02-02 | 2009-09-03 | アラーガン、インコーポレイテッド | 眼系疾患の処置のための組成物および方法 |
| US7601716B2 (en) * | 2006-05-01 | 2009-10-13 | Cephalon, Inc. | Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors |
| WO2007132846A1 (ja) * | 2006-05-16 | 2007-11-22 | Ono Pharmaceutical Co., Ltd. | 保護されていてもよい酸性基を含有する化合物およびその用途 |
| US8080659B2 (en) | 2006-07-11 | 2011-12-20 | Emory University | CXCR4 antagonists including diazine and triazine structures for the treatment of medical disorders |
| US7999107B2 (en) | 2007-01-31 | 2011-08-16 | Merck Sharp & Dohme Corp. | Substituted pyrano[2,3-B]pyridine derivatives as cannabinoid-1 receptor modulators |
| BRPI0909375A2 (pt) | 2008-03-28 | 2015-08-04 | Altiris Therapeutics | Moduladores de receptores de quimiocinas |
| CA2753513C (en) * | 2009-03-02 | 2017-10-10 | Golf Hill Limited | Compounds and methods for treating cancer and viral infections |
| TW201500358A (zh) | 2010-12-16 | 2015-01-01 | 赫夫門羅氏藥廠股份有限公司 | 三環ｐｉ３ｋ抑制劑化合物及其使用方法 |
| RU2013138835A (ru) | 2011-02-09 | 2015-03-20 | Ф. Хоффманн-Ля Рош Аг | Гетероциклические соединения в качестве ингибиторов pi3 киназы |
| CA3008279A1 (en) | 2015-12-14 | 2017-06-22 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
| CN109069426B (zh) | 2015-12-14 | 2021-10-29 | X4 制药有限公司 | 治疗癌症的方法 |
| WO2017112894A1 (en) | 2015-12-22 | 2017-06-29 | X4 Pharmaceuticals, Inc. | Methods for treating immunodeficiency disease |
| CA3019394A1 (en) | 2016-04-08 | 2017-10-12 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
| CN109640988A (zh) | 2016-06-21 | 2019-04-16 | X4 制药有限公司 | Cxcr4抑制剂及其用途 |
| EP3472129A4 (en) | 2016-06-21 | 2019-12-04 | X4 Pharmaceuticals, Inc. | CXCR4 INHIBITORS AND USES THEREOF |
| ES2870920T3 (es) | 2016-06-21 | 2021-10-28 | X4 Pharmaceuticals Inc | Inhibidores de CXCR4 y usos de los mismos |
| WO2019126106A1 (en) * | 2017-12-19 | 2019-06-27 | X4 Pharmaceuticals, Inc. | Acyclic cxcr4 inhibitors and uses thereof |
| WO2020010290A1 (en) | 2018-07-05 | 2020-01-09 | Abb Schweiz Ag | Technologies for solar power system performance model tuning |
| US10548889B1 (en) * | 2018-08-31 | 2020-02-04 | X4 Pharmaceuticals, Inc. | Compositions of CXCR4 inhibitors and methods of preparation and use |
| WO2020117782A1 (en) * | 2018-12-03 | 2020-06-11 | The University Of North Carolina At Chapel Hill | Methods for attenuating graft-versus-host disease and opportunistic infections |
| CA3171250A1 (en) | 2020-03-10 | 2021-09-16 | E. Lynne KELLEY | Methods for treating neutropenia |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4933447A (en) * | 1987-09-24 | 1990-06-12 | Ss Pharmaceutical Co., Ltd. | Quinoline derivatives |
| US6001826A (en) * | 1989-12-21 | 1999-12-14 | Anormed, Inc. | Chemical compounds |
| US5021409A (en) * | 1989-12-21 | 1991-06-04 | Johnson Matthey Plc | Antiviral cyclic polyamines |
| GB9126677D0 (en) * | 1991-12-16 | 1992-02-12 | Johnson Matthey Plc | Improvements in chemical compounds |
| GB9400411D0 (en) * | 1994-01-11 | 1994-03-09 | Johnson Matthey Plc | Improvements in chemical compounds |
| US6506770B1 (en) * | 1996-06-06 | 2003-01-14 | Anormed, Inc. | Antiviral compounds |
| GB9511357D0 (en) * | 1995-06-06 | 1995-08-02 | Johnson Matthey Plc | Improved antiviral compounds |
| AU740603B2 (en) | 1997-06-02 | 2001-11-08 | Janssen Pharmaceutica N.V. | (imidazol-5-yl)methyl-2-quinolinone derivatives as inhibitors of smooth muscle cell proliferation |
| CA2296314A1 (en) | 1997-07-25 | 1999-02-04 | Merck & Co., Inc. | Cyclic amine modulators of chemokine receptor activity |
| KR20010015639A (ko) | 1997-09-30 | 2001-02-26 | 스즈키 다다시 | 술포닐 유도체 |
| US6365583B1 (en) * | 1999-02-02 | 2002-04-02 | Anormed, Inc. | Methods to enhance white blood cell count |
| AP1654A (en) | 1999-03-24 | 2006-09-01 | Anormed Inc | Chemokine receptor binding heterocyclic compounds. |
| US6683192B2 (en) * | 2000-03-30 | 2004-01-27 | Curis, Inc. | Small organic molecule regulators of cell proliferation |
| DE60137435D1 (de) | 2000-09-15 | 2009-03-05 | Anormed Inc | Chemokin rezeptor bindenden heterozyklische verbindungen |
| US6734191B2 (en) | 2000-09-15 | 2004-05-11 | Anormed, Inc. | Chemokine receptor binding heterocyclic compounds |
| HK1052011A1 (zh) * | 2000-09-15 | 2003-08-29 | Anormed Inc. | 趋化因子受体结合杂环化合物 |
| NZ526622A (en) * | 2000-12-11 | 2006-07-28 | Amgen Sf Llc | CXCR3 antagonists |
| US6794379B2 (en) * | 2001-06-06 | 2004-09-21 | Tularik Inc. | CXCR3 antagonists |
| US7169750B2 (en) | 2001-07-31 | 2007-01-30 | Anormed, Inc. | Methods to mobilize progenitor/stem cells |
| DK1411918T3 (da) * | 2001-07-31 | 2012-04-23 | Genzyme Global S A R L | Fremgangsmåder til at mobilisere progenitor/stamceller |
| US8178123B2 (en) * | 2001-08-29 | 2012-05-15 | Femina Pharma Incorporated | Method for augmentation of intraepithelial and systemic exposure of therapeutic agents having substrate activity for cytochrome P450 enzymes and membrane efflux systems following vaginal and oral cavity administration |
| JP4431389B2 (ja) | 2001-09-12 | 2010-03-10 | アノーメッド インコーポレイティド | 鏡像異性的に純粋なアミノ置換縮合二環式環の合成 |
| PL369856A1 (en) * | 2001-12-21 | 2005-05-02 | Anormed Inc. | Chemokine receptor binding heterocyclic compounds with enhanced efficacy |
| US7354932B2 (en) | 2001-12-21 | 2008-04-08 | Anormed, Inc. | Chemokine receptor binding heterocyclic compounds with enhanced efficacy |
| WO2004091518A2 (en) | 2003-04-11 | 2004-10-28 | Anormed Inc. | Cxcr4 chemokine receptor binding compounds |
| EP1730113B1 (en) | 2004-03-15 | 2016-12-28 | Genzyme Corporation | Process for the synthesis of a cxcr4 antagonist |
| TW200619206A (en) * | 2004-09-29 | 2006-06-16 | Anormed Inc | Chemokine-binding heterocyclic compound salts, and methods of use thereof |
-
2003
- 2003-06-06 US US10/457,034 patent/US7354932B2/en not_active Expired - Lifetime
-
2004
- 2004-05-21 JP JP2006533279A patent/JP2007502864A/ja active Pending
- 2004-05-21 EP EP04752905A patent/EP1628533A4/en not_active Withdrawn
- 2004-05-21 CA CA2522535A patent/CA2522535C/en not_active Expired - Lifetime
- 2004-05-21 WO PCT/US2004/015977 patent/WO2004106493A2/en not_active Ceased
-
2008
- 2008-02-22 US US12/036,187 patent/US20080167341A1/en not_active Abandoned
-
2012
- 2012-01-25 US US13/358,041 patent/US8778967B2/en not_active Expired - Lifetime
-
2014
- 2014-06-12 US US14/302,828 patent/US20150038509A1/en not_active Abandoned
-
2016
- 2016-02-08 US US15/018,698 patent/US10322111B2/en not_active Expired - Lifetime
-
2019
- 2019-04-10 US US16/380,365 patent/US20200000774A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007502864A5 (https=) | ||
| US20230233579A1 (en) | Anti-cancer effects of jak2 inhibitors in combination with thalidomide derivatives and glucocorticoids | |
| CA2522535A1 (en) | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | |
| RU2004105961A (ru) | Способы активации клеток-предшественников/стволовых клеток | |
| Cai et al. | The specific roles of JAK/STAT signaling pathway in sepsis | |
| Guinan et al. | Intravascular hemolysis and renal insufficiency after bone marrow transplantation | |
| JP2006526646A5 (https=) | ||
| Hesse et al. | Layered double hydroxides as efficient drug delivery system of ciprofloxacin in the middle ear: an animal study in rabbits | |
| Loftus et al. | The postinjury inflammatory state and the bone marrow response to anemia | |
| JP2013231086A (ja) | 化学療法の強化方法 | |
| JP2007534730A (ja) | 少なくとも一つのピロロベンゾジアゼピン誘導体とフルダラビンとを含有する治療用組成物 | |
| Couban et al. | Bone marrow mobilized with granulocyte colony-stimulating factor in related allogeneic transplant recipients: a study of 29 patients | |
| JP2024519845A5 (https=) | ||
| KR20130142164A (ko) | 암 치료 및 면역억제를 위한 시로신고핀과 미토콘드리아 억제제의 조합물 | |
| JP2005532373A5 (https=) | ||
| JP5457196B2 (ja) | Ｃｎｄａｃ（２’−シアノ−２’−デオキシ−ｎ４−パルミトイル−１−ベータ−ｄ−アラビノフラノシル−シトシン）及び細胞毒性薬を含む組合せ | |
| JP5818905B2 (ja) | エリスロポエチン産生促進剤 | |
| Maron-Gutierrez et al. | Insult-dependent effect of bone marrow cell therapy on inflammatory response in a murine model of extrapulmonary acute respiratory distress syndrome | |
| Russo et al. | Chemotherapy-induced neutropenia elicits metastasis formation in mice by promoting proliferation of disseminated tumor cells | |
| TWI245643B (en) | Composition for selective cancer chemotherapy | |
| RU2008151054A (ru) | Применение ингибиторов рецептора эндотелиального фактора роста сосудов для лечения рака | |
| PT2754441E (pt) | Composição para a prevenção e tratamento de cancro do pulmão de não pequenas células, contendo derivados de pirazino-triazina | |
| Fowler et al. | Targeting the canonical nuclear factor-κB pathway with a high-potency IKK2 inhibitor improves outcomes in a mouse model of idiopathic pneumonia syndrome | |
| WO2022200926A1 (en) | Use of the sesquiterpene lactone tomentosin in the treatment of tumors caused by lymphoid cell lines | |
| CN113694205A (zh) | 5-ht受体抑制剂和顺铂在制备治疗肝癌的药物中的应用 |